2020年度肺癌放射治疗领域研究进展

doi:10.3969/j.issn.2097-0005.2021.05.001

betway必威登陆网址（betway.com ）学报 ›› 2021, Vol. 42 ›› Issue (5): 321-326.DOI: 10.3969/j.issn.2097-0005.2021.05.001

• 特邀专论 • 下一篇

2020年度肺癌放射治疗领域研究进展

刘洁, 李炫宗, 于金明

betway必威登陆网址附属肿瘤医院放疗科,山东济南 250117

收稿日期:2020-12-30 出版日期:2021-05-25 发布日期:2021-08-31
通讯作者: 于金明,中国工程院院士,E-mail:sdyujinming@163.com。
作者简介:刘洁,博士,研究方向:肿瘤放射治疗学,E-mail:linchuangliujie@163.com。
基金资助:
国家重点研发计划(2018YFC1313201);国家自然科学基金重点项目(82030082)。

Research on the progress in radiotherapy of lung cancer in 2020

Liu Jie, Li Xuanzong, Yu Jinming

Department of Radiation Oncology, Affiliated Tumor Hospital of Shandong First Medical University, Jinan 250117,China

Received:2020-12-30 Online:2021-05-25 Published:2021-08-31

摘要/Abstract

摘要： 放疗作为肺癌主要的治疗方式之一,在肺癌全程管理中均发挥重要作用。2020年肺癌放疗领域成绩瞩目,放疗免疫联合治疗依然是热点,靶向联合放疗策略及放疗剂量和技术选择备受瞩目。本文对2020年度肺癌放疗领域的重要研究进行归纳总结。

关键词: 2020年, 肺癌, 放疗, 进展

Abstract: As one of the main treatment methods, radiotherapy plays a very important role in all the stages for lung cancer. Outstanding results were achieved in radiotherapy in lung cancer during 2020. Radiotherapy combining with immunotherapy is still the research hot topic. Radiotherapy combined with targeted therapy, and the choice of radiotherapy dose and technology have attracted much attention. This article reviews the important research progress of radiotherapy in the treatment of lung cancer in 2020.

Key words: 2020, lung cancer, radiotherapy, progression

中图分类号:

R734.2

刘洁, 李炫宗, 于金明. 2020年度肺癌放射治疗领域研究进展[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(5): 321-326.

Liu Jie, Li Xuanzong, Yu Jinming. Research on the progress in radiotherapy of lung cancer in 2020[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(5): 321-326.

参考文献

[1] Gao S, Li N, Wang S, et al. Lung cancer in people's republic of China[J]. J Thorac Oncol, 2020, 15(10):1567.
[2] Kelly K, Daly ME, Mirhadi A, et al. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9011.
[3] Chang JY, Lin SH, Yao L, et al. I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9035.
[4] Lemmon C, Videtic G, Murthy SC, et al. A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9009.
[5] Alex, Herskovic, Elizabeth, et al. Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective nationwide oncology outcomes database[J]. Journal of Thoracic Oncology, 2017, 12:302.
[6] LePe C. An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of Lung ART. 2020 ESMO Abstract LBA3_PR.
[7] Gray JE, Villegas A, Daniel D, et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-update from PACIFIC[J]. J Thorac Oncol, 2020,15(2):288.
[8] Faivre-Finn C. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial[J]. J Thorac Oncol, 2020,16(5):860.
[9] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179[J]. Cancer, 2020,126(19):4353.
[10] Melissa Y. Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemotherapy in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial. 2020 ASCO Abstract 9010.
[11] Jabbour SK, Lee KH, Frost N, et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9008.
[12] Helen JR. AFT-16: Phase II trial of atezolizumab before and after definitive chemotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC). 2020 ASCO Abstract 9045.
[13] Bi N, Wang L, Xu K, et al. Real-world treatment patterns and clinical outcomes in EGFR-mutant unresectable locally advanced NSCLC (LA-NSCLC): A retrospective multicenter study of 367 patients[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9047.
[14] Xing L, Wu G, Wang L,et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: A multicenter, randomized, open-label, phase 2 trial[J]. Int J Radiat Oncol Biol Phys,2020,19:S0360-3016(20)34548-X.
[15] Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015,16(2):187.
[16] Bradley JD, Hu C, Komaki RR, et al. Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer[J]. J Clin Oncol, 2020,38(7):706.
[17] Yuan S, Yu Q, Wang S, et al. Individual adaptive radiotherapy versus standard radiotherapy with chemotherapy for patients with locally advanced non-small cell lung cancer: A multicenter randomized phase III clinical trail CRTOG 1601[J]. International Journal of Radiation Oncology*Biology*Physics, 2020,108(3):S105.
[18] Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial[J]. JAMA Oncol, 2019,5(9):1276.
[19] Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Respir Med, 2020,20:S2213-2600(20)30391-X.
[20] Chmura SJ, Bestvina CM, Karrison TG, et al. Safety and efficacy of a randomized phase I trial to evaluate concurrent or sequential Ipilimumab, Nivolumab, and Stereotactic body radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study)[J]. International Journal of Radiation Oncology Biology Physics, 2020,108( 3): S72.
[21] Wang X, Bai YF, Zeng M. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFR ilogometastatic ono-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS)(NCT02893332)[J]. Oncology*Biology*Physics,2020,108(3 Supplement):e81.
[22] Peters S, Pujol J, Dafni U, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial[J]. Annals of Oncology,2020,31(4 Supplement): S1211.
[23] Gronberg BH, Killingberg KT, Fltten Y, et al. Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC)[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9007.
[24] Ii C, Movsas B, Gore EM, et al. A phase 1b/2a study evaluating the pharmacokinetic, safety, and efficacy of nanogenistein in combination with chemoradiotherapy for non-small cell lung cancer[J].International Journal of Radiation Oncology*Biology*Physics,2020,108(3):S103.
[25] Tsakiridis T, Pond G, Wright J, et al. Randomized phase II trial of metformin in combination with chemoradiotherapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464)[J]. International Journal of Radiation Oncology Biology Physics, 2020, 108(3):S104.

2020年度肺癌放射治疗领域研究进展

Research on the progress in radiotherapy of lung cancer in 2020

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

[1]	马福静. 盐酸替罗非班治疗进展性脑卒中和短暂性脑缺血发作的临床疗效[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(6): 457-459.
[2]	赵敏, 秦树存. 氢气生物医学效应的发现、研究与应用[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(5): 339-346.
[3]	袁绪龙, 赵嫚, 纪波, 穆玉恕. 非小细胞肺癌患者血脂联合检测分析[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(4): 267-269.
[4]	袁莉, 李素霞, 王卫华. EGFR/TGF-α/P-AKT/PTEN联合检测在非小细胞肺癌中的临床意义及相关性[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(3): 185-189.
[5]	邱玲动, 公丕欣, 柏秀娜, 王慧. Orem理论与快速康复护理在胸腔镜肺癌根治术中的应用[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(2): 108-110.
[6]	金晨, 李矿. 青少年特发性脊柱侧凸的支具治疗进展[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(2): 157-160.
[7]	张旭, 唐根富. H型高血压的研究现状及进展[J]. betway必威登陆网址（betway.com ）学报, 2021, 42(1): 74-77.